News | April 23, 2021
Serum not contracted for complete production of COVID vaccine to centre
These media reports are based on incorrect facts and are without any basis.
These media reports are based on incorrect facts and are without any basis.
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Subscribe To Our Newsletter & Stay Updated
